Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of tolvaptan on renal blood flow and glomerular filtration rate in autosomal dominant polycystic kidney disease
2015-001903-30Phase 2Terminated
- Sponsor
- Department of Medical Research
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Department of Medical Research. Primary endpoint: renal plasma flow. Started May 2015; status: terminated.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2015-001903-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001903-30.